Michael Chenier
Interventional Cardiology · Cleveland, OHNPI 1902049794
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (39.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Shockwave Medical, Inc at 42.2% of the total. 2025 is the largest year on record at $40,894, more than ten times the $1,033 reported in 2019.
Across 270 payments — averaging $282.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$32K
- Medtronic$29K
- Abbott$13K
- Boston Scientific$497
- Cardiva Medical, Inc.$322
- E.r. Squibb & Sons, L.L.C.$281
- plus $1K from 11 others
Across 41 payments — averaging $1120.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$37K
- Medtronic$9K
What the payments were for
- Consulting fees$29,85039%
- Speaking & faculty fees$22,54130%
- Travel & lodging$12,81717%
- Food & beverage$11,17215%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 22 | $32,249 |
| Medtronic(2 entities) | 73 | $28,857 |
| Abbott | 109 | $12,994 |
| Boston Scientific | 11 | $497 |
| Cardiva Medical, Inc. | 21 | $322 |
| E.r. Squibb & Sons, L.L.C. | 3 | $281 |
| Abiomed | 6 | $274 |
| Boehringer Ingelheim | 2 | $237 |
| Cardiovascular Systems Inc. | 7 | $185 |
| Edwards Lifesciences | 1 | $130 |
| Atricure, Inc. | 3 | $124 |
| Philips North America LLC | 2 | $73 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $60 |
| Pfizer | 2 | $49 |
| Teleflex LLC | 1 | $18 |
| W. L. Gore & Associates, Inc. | 1 | $16 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$32,057
- COREVALVE EVOLUT R$27,273
- NAVITOR$5,321
- MitraClip$2,322
- AMPLATZER TALISMAN$1,000
- Mitra Clip system$281
- PORTICO$281
- JARDIANCE$237
- General - Balloon Catheters$149
- WATCHMAN FLX$145
- COROFLOW$135
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$130
- Impella$125
- CAMZYOS$125
- DRAGONFLY OPSTAR$109
How this compares
$76,380 in reported general payments places this provider in the 85th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 210 | $225,638 |
| EntrestoSacubitril/Valsartan | 91 | $110,778 |
| XareltoRivaroxaban | 77 | $87,252 |
| Repatha SureclickEvolocumab | 44 | $30,466 |
| Praluent PenAlirocumab | 24 | $21,121 |
| Repatha SyringeEvolocumab | 17 | $11,547 |
| MultaqDronedarone Hcl | 13 | $9,756 |
| JardianceEmpagliflozin | 13 | $8,748 |
| Metoprolol Succinate | 306 | $3,419 |
| Dofetilide | 22 | $3,020 |
| Ranolazine ErRanolazine | 15 | $1,592 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 13 | $1,448 |
| ClopidogrelClopidogrel Bisulfate | 152 | $1,438 |
| Atorvastatin Calcium | 193 | $1,176 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 124 | $1,102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $49 | $225,638210 claims |
| Boehringer IngelheimJardiance | $237 | $8,74813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Cleveland
- Grant ReedCleveland$235K
- Rishi PuriCleveland$185K
- Rayji TsutsuiCleveland$100K
- Paul PoommipanitCleveland$97K
- Jun LiCleveland$85K
- Khaled ZiadaCleveland$53K
- Laura YoungCleveland$51K
- Bernardo CorteseCleveland$45K
- Jason WenCleveland$37K
- Khanjan ShahCleveland$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.